SCHEMBL3538283

SCHEMBL3538283

CCn1c(C2CC2)c(Br)c(=O)n1-c1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.37
GRM2 Q14416 1/20 0.37
ALOX5 P09917 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 2/20 0.36
FAAH O00519 1/20 0.36
MGLL Q99685 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BPTF Q12830 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
KDM4E B2RXH2 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
METAP2 P50579 1/20 0.33
MPI P34949 1/20 0.33
PDE1C Q14123 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530319 0.88 HSD11B1 (0.42) HSD11B1GRM2ALOX5L3MBTL1ALDH1A1
SCHEMBL3531163 0.86 MEN1 (0.38) HSD11B1GRM2MEN1KMT2AMAPT
SCHEMBL3528519 0.85 HTR7 (0.39) HSD11B1ALOX5L3MBTL1ALDH1A1FAAH
SCHEMBL3529353 0.84 HSD11B1 (0.38) HSD11B1GRM2L3MBTL1ALDH1A1MAPT
SCHEMBL3533392 0.77 GRM2 (0.38) HSD11B1GRM2ALOX5L3MBTL1ALDH1A1
SCHEMBL3528842 0.73 HSD11B1 (0.40) HSD11B1GRM2MEN1KMT2ADRD2
SCHEMBL3534236 0.73 HSD11B1 (0.37) HSD11B1MGLL
SCHEMBL3532450 0.73 HSD11B1 (0.42) HSD11B1ALOX5L3MBTL1ALDH1A1FAAH
SCHEMBL3526545 0.72 CYP3A4 (0.41) HSD11B1L3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL3530868 0.71 HSD11B1 (0.43) HSD11B1GRM2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 HSD11B1 1/4885GRM2 3610/4885ALOX5 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.